key: cord-0849891-rxp5qxwe
authors: Blach, S; Blomé, M; Duberg, A‐S; Jerkeman, A; Kåberg, M; Klasa, P‐E; Lagging, M; Razavi‐Shearer, D; Razavi, H; Aleman, S
title: Hepatitis C Elimination in Sweden: Progress, Challenges and Opportunities for Growth in the time of COVID‐19
date: 2021-05-29
journal: Liver Int
DOI: 10.1111/liv.14978
sha: a78a71dbb3670007a54fd2345d80d7712e2648aa
doc_id: 849891
cord_uid: rxp5qxwe

BACKGROUND & AIMS: In 2014, the burden of hepatitis C virus (HCV) in Sweden was evaluated, to establish a baseline and inform public health interventions. Considering the changing landscape of HCV treatment, prevention, and care, and in light of the COVID‐19 pandemic, this analysis seeks to evaluate Sweden’s progress toward the WHO elimination targets and identify remaining barriers. METHODS: The data used for modeling HCV transmission and disease burden in Sweden were obtained through literature review, unpublished sources, and expert input. A dynamic Markov model was employed to forecast population sizes and incidence of HCV through 2030. Two scenarios (“2019 Base” and “WHO Targets”) were developed to evaluate Sweden’s progress toward HCV elimination. RESULTS: At the beginning of 2019, there were 29,700 (95% UI: 19,300 – 33,700) viremic infections in Sweden. Under the base scenario, Sweden would achieve and exceed the WHO targets for diagnosis, treatment, and liver‐related death. However, new infections would decrease by less than 10%, relative to 2015. Achieving all WHO targets by 2030 would require 1) expanding harm reduction programs to reach more than 90% of PWID and 2) treating 90% of HCV+ PWID engaged in harm reduction programs and ≥7% of PWID not involved in harm reduction programs, annually by 2025. CONCLUSIONS: It is of utmost importance that Sweden, and all countries, find sustainability in HCV programs by broadening the setting and base of providers to provide stability and continuity of care during turbulent times.

In 2014, the burden of hepatitis C virus (HCV) in Sweden was evaluated and published, to establish a baseline and inform public health interventions. 1 Just two years later, the 69 th World Health Assembly unanimously voted to adopt a Global Health Sector Strategy for the elimination of hepatitis as a public health threat by 2030. 2 Those targets include increasing the proportion of diagnosed patients to 90%, increasing treatment coverage to 80%, reducing new infections by 90% and reducing mortality by 65%. 2 Since that initial analysis in 2014, Sweden has made large strides in HCV treatment and prevention.

Access to HCV treatments has been established free of charge to patients through cost sharing agreements with the Swedish states and health care regions (70% of costs covered by the state and 30% covered by the health care region). National treatment guidelines have been expanded to include people who inject drugs (PWID) and those with acute infections. Additionally, harm reduction programs have been established across the country and strengthened to include HCV treatment and care. 3, 4 In Stockholm, harm reduction programs have been effective in lowering the viremic prevalence of HCV among participants from 55% to 40%. 5 The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes coronavirus disease 2019 (COVID-19), resulted in a unique challenge for healthcare systems globally and in Sweden. As of 18 November 2020, 196,446 people in Sweden tested positive for COVID-19 with 6,321 total deaths reported. 6 Although Sweden never experienced a "hard lockdown", COVID-19 impacted HCV care as well as harm reduction and addiction treatment services. Experiences vary by region and clinic and range from disrupted outreach activities (Stockholm) to a temporary pause in treatment starts (Örebro and Skåne) (personal communication with the authors). In Gothenberg, for example, the infectious disease clinic was used as the COVID-19 clinic, resulting in a temporary discontinuation, from April until May 2020, in treatment within that setting.

At a national level, the numbers of patients diagnosed with HCV (as reported to Folkhälsomyndigheten [The Public Health Agency of Sweden]) were reduced by 27% from January

This article is protected by copyright. All rights reserved to October 2020, compared with the same time frame in 2019. 7 Similarly, HCV treatment starts were reduced by 55%, from January to October 2020, compared with the same time frame in 2019 (personal communication with Ola Weiland, InfCare Hepatitis Register). 8 Some reduction in treated patients could be attributed to a waning population of warehoused patients; however, a decrease in newly diagnosed patients and restricted availability to outreach programs was also experienced (either due to not yet started activities or ongoing activities restricted due to . A further concern is that independently of COVID-19, Sweden has experienced large loss to follow up among diagnosed HCV infected patients in care at hospitals with available treatment, identifying an unmet need to expand care beyond this setting 9

Considering the changing landscape of HCV treatment, prevention, and care in Sweden, and in light of the COVID-19 pandemic, this analysis seeks to evaluate Sweden's progress toward the WHO elimination targets and identify remaining barriers.

The data used for modeling were obtained through literature review, unpublished sources, and expert input. Next, a dynamic Markov model was used to forecast the disease burden and transmission of HCV. The methodology for calculating new infections due to transmission among PWID is described in the Appendix. Inputs are included in the appendix and briefly described here.

HCV prevalence, prevalence by age and sex, and the number of persons previously diagnosed and treated were used to seed and calibrate the model. Many of these inputs have been described in detail previously, with newer inputs described briefly here. 1 The annual number of cases notified to the Swedish Public Health Authority was used to estimate the number of persons newly diagnosed.

Beginning in 2020, the basis for notification changed from anti-HCV to HCV-RNA or HCV-Ag, and labs introduced reflex testing for anti-HCV positive samples. To estimate the number of newly diagnosed viremic cases, data reported prior to 2020 were adjusted assuming a viremic rate of 77%. 

This article is protected by copyright. All rights reserved National Board of Health and Welfare. Summing annual treated patients resulted in a total that was ~12% higher than the total unique patients treated, so the annual estimates were adjusted down to account for possible double counting of patients initiating and completing treatment in different years.

An SVR of 95% was considered from 2014-2016, increasing to 97% after 2017. The number of patients transplanted who were positive for anti-HCV from 1990-2018 was provided by Scandiatransplant (Scandiatransplant, 2019 data, requested by Dr. Aleman)

To model transmission of HCV among PWID, data around population size, harm reduction and injecting behaviors were collected from published and unpublished sources and were informed by expert consensus if empirical data were unavailable. PWID was defined as persons who have injected drugs within the last year, with stimulants (59%; primarily amphetamine) and opioids (34%; primarily heroin) as the most frequently injected drugs in Sweden (National InfCare Needle Syringe Program, 2019 data, Dr Kåberg). Participation data for opiate substitution therapy (OST) and needle and syringe programs (NSP) were available through the InfCare NSP quality register and from data reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Assumptions around injecting behavior were available from published sources or estimated using expert consensus.

A full description of the inputs identified for transmission modeling, as well as the value in the year of report, can be found in the Appendix, Section 1.

Additionally, the size of the HCV-infected population in Swedish prisons was estimated using data on the number of prisoners, annual turnover of prisoners and the proportion testing positive for Anti-HCV.

Once the model was developed, a variety of "what-if" scenarios were run to evaluate the impact of future decisions. These scenarios were first envisaged before the COVID-19 pandemic began, but a new scenario has been added to evaluate the impact of real-world delays in treatment that have been experienced in Sweden as a result of the pandemic and is discussed in more detail in the next section.

The scenarios included are as follows:

This article is protected by copyright. All rights reserved A baseline scenario (Base 2019) was developed using empirical diagnosis and treatment data through 2019. After 2019, screening was assumed to remain constant, resulting in fewer newly diagnosed cases each year (Table 1) . Assuming no major improvements in case finding or linkage to treatment or harm reduction, the number of patients starting treatment each year would decrease (Table 1) .

However, as treatment in harm reduction becomes commonplace, the proportion of treatments directed to NSP and OST clients was assumed to increase (assuming a constant proportion of clients on NSP and OST are initiated on treatment each year). This assumes that outreach programs from hospital settings would be improved substantially, or that prescription/treatment by health-care providers outside of hospital settings (usually from department of Infectious Diseases in Sweden) would be routine practice.

Additionally, a scenario was developed to identify the steps needed to achieve the WHO elimination targets (90% diagnosed; 80% treated; 65% reduction in mortality; 90% reduction in incidence) by 2030 (WHO 2030). This scenario considered increased diagnosis and treatment both in the general population and among PWID. With the PWID population, the impact of increased uptake of harm reduction services was also calculated ( Table 1) .

Crystal Ball release 11.1.2.3.500 was used to calculate uncertainty intervals (UIs) and conduct sensitivity analyses. β-PERT distributions were used for all uncertain inputs. A Monte Carlo simulation with 1,000 trials was used to estimate 95% UIs.

To evaluate the impact of COVID-19 on elimination efforts, the number of patients initiated on treatment per month in 2019 and 2020 were accessed through the IQVIA prescription claims database (IQVIA, formerly QuintilesIMS, is a large aggregator of pharmacy and prescription data). Projections based on monthly diagnosis and treatment data from the first half of 2020 were used to estimate the number of patients treated in 2020. Since the full extent of disruptions due to COVID-19 are yet to be seen, a variety of sensitivity analyses were explored and compared assuming changing treatment levels over the next 5 years.

This article is protected by copyright. All rights reserved

To examine the impact of faster scale-ups in harm reduction services, three scenarios achieving 90% of PWID engaged in NSP by 2023 were also developed, as follows: 1) 90% of PWID engaged in NSP by 2023, no treatment; 2) 90% of PWID engaged in NSP by 2023, treatment at base levels; 3) 90% of PWID engaged in NSP by 2023, WHO Targets.

At the beginning of 2019, there were an estimated 29,700 (95% UI: 19,300 -33,700) viremic infections in Sweden [0.30% (95% UI: 0.19% -0.34%) HCV-RNA+]. Of these, more than 80% had already been diagnosed; however, due to incomplete linkage to care and loss to follow-up, fewer than 20% of prevalent infections were initiated on treatment in the same year ( Figure 1 ). There were an estimated 21,000 PWID in Sweden, more than half of whom primarily injected amphetamines.

Approximately 23% of PWID were engaged in harm reduction (NSP, OST or both) programs and 10,500 of all PWID were HCV-RNA+ ( Figure 2 ). Within harm reduction programs, an estimated 15% of NSP participants and 26% of PWID on OST were initiated on HCV treatment annually, or approximately 540 PWID treated in 2018. In 2019, the model calculates that there would be 1,200 new HCV infections (including reinfection) occurring annually (incidence rate 28.7/100) . Since the risk of transmitting HCV decreases among PWID engaged in harm reduction services, the majority of new infections (>80%) were estimated to occur among PWID who were not in contact with harm reduction services.

Before considering the impact of COVID-19, 1,070 persons were estimated to be newly diagnosed with viremic HCV in Sweden with 3,200 initiated on treatment in 2020. These estimates would represent a consistent number of annually diagnosed new infections and a decrease in treated patients from 4,800 in 2019. However, data from the first ten months of 2020 suggest that the actual number of new viremic diagnoses will be closer to 778, a 27% reduction from 2019 (Appendix, Section 2).

Similarly, InfCare Hepatitis data suggest that only 2,110 patients would be forecast to receive HCV treatment in 2020, a 56% reduction relative to the number of patients treated in 2019, and 34% lower than initial (pre-COVID-19) forecasts for 2020 (Appendix, Section 2).

This article is protected by copyright. All rights reserved Under the 2019 base scenario, Sweden was projected to achieve and exceed the WHO targets for diagnosis, treatment, and liver-related deaths ( Figure 3 ). Current efforts to treat HCV among PWID in OST and NSP would reduce total prevalent infections; however, new infections were projected to decrease by less than 10% relative to a 2015 comparison point (Table 3) . Under this scenario, 9, 700 people would be newly diagnosed and 24,200 initiated on treatment between 2021 and 2030, leading to an 87% reduction in liver related deaths by 2030.

Considering the impact of COVID-19 in 2020, and assuming the number of patients diagnosed and initiated on treatment returned to previously forecasted levels by 2021, Sweden would still achieve the targets for diagnosis, treatment and mortality, but would not achieve the target for incidence. Achieving all of the WHO targets by 2030 would require increased efforts to sustain and expand treatment in hard-to-reach populations. Outreach programs with easier access to HCV treatment, with expansion of HCV treatment beyond hospital-settings would be needed to sustain the treatment rate.

Another option would be to broaden the provider base with prescription of HCV drugs of physicians in NSP, OST, primary care, etc. Harm reduction programs would need to expand to cover at least 80% of PWID. Although this could be achieved through a variety of scenarios, the scenario modeled here included a 12% annual increase in participants accessing NSP programs and a 10% annual increase in participants accessing OST, beginning in 2020, to reach ≥90% coverage by 2030. Next, 90% of PWID engaged in harm reduction settings would need to be initiated on HCV treatment annually by 2025. This could be achieved through linear increases in the proportion of patients treated annually beginning in 2021 ( Figure 4) . Finally, linear increases in the proportion of PWID treated for HCV outside of harm reduction settings would need to reach 7% annually (maximum 290 patients annually) by 2025 ( Figure 4 ).

Increasing PWID engagement in NSP programs to reach 90% by 2023, could reduce the number of new infections among PWID by 27%, even in the absence of treatment (Appendix, Section 4). When

This article is protected by copyright. All rights reserved combined with base treatment levels, incidence could be reduced by 55%. The WHO targets could be achieved with 90% of PWID engaged in NSP by 2023, with 21% of HCV+ PWID treated annually (among PWID engaged in harm reduction settings) (Appendix, Section 4).

Before the COVID-19 pandemic introduced disruptions to hepatitis testing and care, Sweden was already experiencing a decline in the number of patients initiating treatment annually. Although Sweden was on-track to meet most of the WHO targets by 2030, a 90% reduction in incidence could not be achieved. Using a dynamic transmission model based on the inputs described in Appendix, Section 1, our study calculated an annual HCV incidence rate of 29/100 PWID, among PWID sharing injecting equipment. This is in line with a recent study in NSP participants, which found an annual incidence rate of 22/100 person years (26/100 among HCV naïve and 19/100 among the spontaneously cleared group). 13 Temporary declines in HCV treatment due to COVID-19 were not found to impact long-term progress toward these targets (i.e., the targets Sweden was projected to achieve under the 2019 base scenario would still be achieved, and targets Sweden was not projected to achieve under the 2019 base scenario would still not be achieved). However, excess morbidity and mortality would be expected, with increasing burden associated with longer disruptions to care.

A perhaps greater concern is that although more than 80% of HCV+ patients in Sweden currently are estimated to have been diagnosed most Infectious Diseases clinics no longer have patients waiting for treatment. As a result, the number of patients treated annually is declining. The proportion of people previously diagnosed is based on cases notified to the PHA and previous publications 1 ; however, this estimate has not been assessed by any recent general population studies. One study among pregnant women and their partners found that more than 83% of persons testing positive for HCV-RNA had been previously diagnosed, and more than 50% of the diagnosed persons were previously lost to follow up. 14 In order to eliminate HCV, all previously diagnosed patients need to be re-screened or reidentified and linked to care -either in a traditional setting or in a setting in which they are already linked to care (for example, prisons, NSP, addiction clinics, treatment homes, etc.). During the COVID-19 pandemic, screening activities for HCV seem to have decreased across settings, including primary care, with fewer referrals to HCV care centers in hospital settings as well as delays in Accepted Article scheduling among patients referred to Infectious Disease clinics (personal communication with the authors). This is likely due to a combination of factors, including limited physical visits by some health care facilities and also fewer visits by the patients for fear for COVID-19. Also, the introduced initiatives of outreach programs from departments of Infectious diseases at the hospital settings may have reduced substantially due to the ongoing pandemic. All of this underscores the need for developing sustainability in treatment for HCV amidst COVID-19. This includes increasing the access to treatment by outreach programs through different settings, broadening provider base, and meeting patients where they are at.

To reduce HCV related mortality, continued screening for HCC with early detection of cancer in patients with liver cirrhosis is important. However, patient concerns about the safety of healthcare facilities due to COVID-19 may prevent them from seeking care. Clear messaging is needed to ensure continuity of care, especially for patients who are most at risk. One limitation of our study is that HCV-related mortality was calculated within the model, rather than evaluated using empirical data from Sweden, and is presented as the number of deaths among persons who are still HCV-RNA+.

However, a reduction in mortality is supported by the results of a recent systematic review which found SVR attainment to be a significant predictor of reduced mortality. 15 Achieving the WHO targets can only be accomplished through the continued expansion of harm reduction services and treatment of high-risk populations. Increased access to OST programs is necessary; however, at least 50% of PWID in Sweden inject amphetamines and would not be reached by these efforts. As a result, NSP expansion in Sweden should be of primary importance to reach PWID in general and PWID who use amphetamine in particular. 16 NSP programs were first introduced in Sweden in 1986, but only began to scale up in 2017 following a change in law (more details in Appendix, Section 1). By the end of 2017, 8 (of 21) regions offered NSP programs, which increased to 16 regions by the end of 2019. However, although services may be available across most/all regions, that does not guarantee that PWID will access services at the same rate. Access to HCV treatment within harm reduction settings has improved substantially over the last few years and contributed to declining prevalence among participants, providing benefit not only to the individuals cured of their HCV infection, but also reducing the likelihood of HCV transmission. However,

This article is protected by copyright. All rights reserved increasing the number of avenues for accessing HCV treatment is sorely needed and can include increased providers in harm reduction settings, psychiatry settings, substance use disorder settings and prison settings.

A number of challenges remain, including identifying patients through new screening efforts or by tracking down patients previously lost to follow up. HCV is a notifiable disease, so all persons diagnosed with HCV are included in national registers. For the last few years, regions have been using these registers to try to reach patients who have been lost to follow-up. However, this approach is complicated since some patients are hard to reach or may not be interested in further testing and treatment. This is amplified among legal minors who inject drugs as they are restricted by Swedish legislation from accessing NSP programs. Further challenges may include convincing patients of the importance of treatment and/or prevention measures to avoid transmission or re-infection.

Underscoring all of this work is a need for sustainability in HCV outreach and care programs that meet patients where they are. The traditional model of HCV treatment in infectious disease clinics and hospital settings is insufficient for HCV elimination, as has been exposed through the COVID-19 pandemic. Expanded access to care should include education for all health care providers who interact with HCV positive persons, providing more access points for HCV diagnosis, treatment, and care.

Peer support through local drug user unions should be sought to alleviate loss to follow up and facilitate HCV treatment among PWID. And timely, ongoing, HCV screening with reliable linkage to treatment and care will be important for quickly identifying new infections and re-infections before patients are lost to follow up. Lastly, current regional reimbursement challenges may discourage smaller practices from treating for HCV, which should be addressed.

COVID-19 has impacted HCV treatment as well as NSP and OST in Sweden; but the full extent of the disruptions is yet to be seen. As a result, it is of utmost importance that Sweden, and all countries, find sustainability in treatment by broadening the setting and base of providers to provide stability and continuity of care during turbulent times. Through increased harm reduction efforts and treatment among PWID, Sweden can reduce the incidence of HCV by 90% by 2030 and achieve the WHO

This article is protected by copyright. All rights reserved targets. This will require a concerted effort and prioritization of hepatitis at a time when patients may be reluctant or unable to seek traditional care.

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

This article is protected by copyright. All rights reserved 

Section 1

The model calculated new infections among PWID dynamically, considering the probability of infection, size of the susceptible population and proportion of the population sharing needles.

Among PWID who did not share injecting equipment, the probability of infection was calculated considering only the background HCV prevalence in Sweden. For PWID who shared injecting equipment, the probability of infection was calculated using the average annual number of unsafe injections, HCV prevalence among shared syringes, and probability of HCV transmission from a contaminated needle (5% 1 ). Participation in an NSP was assumed to result in a 30% reduction in unsafe injections, with OST participation resulting in a 50% reduction in unsafe injections.

Simultaneous involvement in an NSP and OST was assumed to result in an 75% reduction in unsafe injections. [2] [3] [4] [5] [6] [7] Inputs Identified for Transmission Modeling

In 2015, there were an estimated 21,000 people who inject drugs (PWID), in Sweden. This was estimated assuming 10,000 injecting opioid users and 11,000 injecting amphetamine users 8 

This article is protected by copyright. All rights reserved

The HCV prevalence in OST populations is estimated to be around 50%, with a higher prevalence among NSP participants (closer to 60%). Overall, the group decided a 50% viremic prevalence for all PWID would be reasonable in 2018. The number of PWID initiating DAA treatment per year is uncertain. Treatment is available in OST centers, with some treatment also available onsite at a limited number of NSP. In addition, some PWID who are engaged with NSP or OST programs are treated off-site, where treatment is not available on-site. *The scenario to discontinue treatment (zero patients treated after 2020) has not been described in-text, as it is highly unlikely to occur. However, it is provided here to show a "worst-case" scenario. 

This article is protected by copyright. All rights reserved This article is protected by copyright. All rights reserved

The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies

Global health sector strategy on viral hepatitis 2016-2021, Towards ending viral hepatitis

Treatment of hepatitis C virus infection: updated Swedish Guidelines

Drug treatment of hepatitis C virus infection in adults and children

Sprututbytet i Stockholm Verksamhetsberättelse

Number of cases of covid-19 in Sweden

The Public Health Agency of Sweden

Data & Statistics: Hepatitis C

Frequent loss to follow-up after diagnosis of hepatitis C virus infection: A barrier towards the elimination of hepatitis C virus

Accepted Article This article is protected by copyright. All rights reserved

Lookback screening for the identification of transfusion-induced hepatitis C virus infection in Sweden

Hepatitis C infection among injection drug users in Stockholm Sweden: prevalence and gender

with generous sampling for hepatitis C after blood transfusion. The National Board of Health and Welfare's new recommendation for risk groups

Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange-Importance for HCV elimination

Anti-HCV prevalence and risk factor-based screening for hepatitis C in pregnant women and their partners in Sweden

Impact of direct-acting antiviral regimens on mortality and morbidity outcomes in patients with chronic hepatitis c: Systematic review and meta-analysis

Treatment of hepatitis C at the Stockholm needle syringe programtreatment success, reinfection rates and challenges for HCV elimination

Recommendations for follow-up of health care workers after occupational exposure to hepatitis C virus

Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users

The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence

Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users

Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study

Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs

Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness

Hepatitis C virus infection in patients receiving opiate substitution therapy in Sweden

Significant decrease in injection risk behaviours among participants in a needle exchange programme

International epidemiology of HIV and AIDS among injecting drug users

Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program

Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program

Vaccination against hepatitis B virus among people who inject drugs -A 20year experience from a Swedish needle exchange program

Could 30 years of political controversy on needle exchange programmes in Sweden contribute to scaling-up harm reduction services in the world?

The Public Health Agency of Sweden

Treated Treated Patients -WHO Targets

General Population No Harm Reduction